This Article Full Text Full Text (PDF) A correction has been published Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Frank-Raue, K. Articles by Meng, W. Search for Related Content PubMed PubMed Citation Articles by Frank-Raue, K. Articles by Meng, W. Related Collections Calcium and Bone Metabolism Endocrine Oncology

Coincidence of Multiple Endocrine Neoplasia Types 1 and 2: Mutations in the RET Protooncogene and MEN1 Tumor Suppressor Gene in a Family Presenting with Recurrent Primary Hyperparathyroidism

Endocrine Practice (K.F.-R., S.R., F.R.), D-69120 Heidelberg, Germany; Institute of Hormone Research (W.H.), 20251 Hamburg, Germany; Department of Surgery (P.G.), Lukas Krankenhaus, 41464 Neuss, Germany; and Department of Internal Medicine (W.M.), University of Greifswald, 17487 Greifswald, Germany

Address all correspondence and requests for reprints to: Priv. Doz. Dr. Med. Karin Frank-Raue, Endokrinologische Gemeinschaftspraxis, Brückenstrasse 21, D-69120 Heidelberg, Germany. E-mail: karin.frankraue{at}raue-endokrinologie.de.

Context: Primary hyperparathyroidism (HPT) presents as a part of inherited syndromes such as multiple endocrine neoplasia (MEN) types 1 and 2. In patients with MEN1, parathyroid hyperplasia or multiple adenomas occur in approximately 90–95%. MEN2A-related HPT is characterized by a mild hypercalcemia, which is mostly asymptomatic.

Objective: Here we present a family with coexistence of MEN1 gene mutation and RET mutation.

Results: Six family members carrying MEN1 gene mutation IVS5 + 1G>A only, one family member with RET mutation Y791F, and three family members with both MEN1 gene and RET mutation were studied. The key to diagnosis was recurrent HPT in a young male carrying RET mutation Y791F, a mutation not likely to give rise to recurrent HPT.

Conclusion: MEN1 gene mutation and RET codon 791 mutation in the same patient did not affect the typical phenotype of MEN1 or MEN2, and also the course of diseases seems to be unchanged. The reason may be that both mutations, although contributing to tumor pathogenesis, do not interact and induce a worsening of the cancer syndromes.

This article has been cited by other articles:

				M. Colombo-Benkmann, Z. Li, B. Riemann, K. Hengst, H. Herbst, R. Keuser, U. Gross, S. Rondot, F. Raue, N. Senninger, et al. Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma. Eur. J. Endocrinol., June 1, 2008; 158(6): 811 - 816. [Abstract] [Full Text] [PDF]

				K. Frank-Raue, M. Fabel, S. Delorme, U. Haberkorn, and F. Raue Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma Eur. J. Endocrinol., August 1, 2007; 157(2): 215 - 220. [Abstract] [Full Text] [PDF]